<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35188698</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>09</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1468-1331</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>29</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>European journal of neurology</Title>
          <ISOAbbreviation>Eur J Neurol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Association of immunosuppression treatment with generalization among patients with ocular myasthenia gravis: A propensity score analysis.</ArticleTitle>
        <Pagination>
          <StartPage>1805</StartPage>
          <EndPage>1814</EndPage>
          <MedlinePgn>1805-1814</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/ene.15292</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">To analyze disease generalization in patients with ocular myasthenia gravis (OMG) treated with immunosuppression compared with patients without immunosuppression treatment.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">In this retrospective cohort study, we analyzed data from patients with OMG at seven medical centers in China from January 1, 2015 to May 1, 2019 and compared disease generalization in patients (treated with immunosuppression vs. not treated) within 2 years of disease onset using raw and inverse probability of treatment weighting (IPTW) analyses.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">In the study population of 813 patients with OMG, 425 (52.3%) with immunosuppression had a mean (SD) onset age of 50.0 (15.1) years, and 188 (44.2%) were women. The remaining 388 (47.7%) patients were not immunosuppressed (mean age, 48.4 [15.0] years; 185 [47.7%] women). Disease generalization developed in 122 (31.4%) and 37 (8.7%) patients in the non-immunosuppression and immunosuppression groups, respectively. Relative to non-immunosuppression, immunosuppression was associated with a lower risk of generalization in a multivariable-adjusted Cox model (hazard ratio [HR] 0.27; 95% confidence interval [CI] 0.18-0.40; p &lt; 0.001) and IPTW-weighted Cox model (HR 0.28; 95% CI 0.19-0.42; p &lt; 0.001). In sensitivity analyses, longer duration of immunosuppression was associated with a lower risk of generalization (HR 0.90 for every 1-month increase; 95% CI 0.87-0.92; p &lt; 0.001; IPTW-adjusted). Combination therapy with steroids and non-steroidal immunosuppressants showed superior efficacy in reducing the risk of generalization (HR 0.14; 95% CI 0.07-0.26; p &lt; 0.001).</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Immunosuppression significantly reduced the 2-year risk of generalization in patients with OMG.</AbstractText>
          <CopyrightInformation>© 2022 European Academy of Neurology.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ruan</LastName>
            <ForeName>Zhe</ForeName>
            <Initials>Z</Initials>
            <Identifier Source="ORCID">0000-0002-8190-4022</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guo</LastName>
            <ForeName>Rongjing</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Hongyu</ForeName>
            <Initials>H</Initials>
            <Identifier Source="ORCID">0000-0002-7637-1305</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, West China Hospital, Sichuan University, Chengdu, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gao</LastName>
            <ForeName>Feng</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neuroimmunology, Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lin</LastName>
            <ForeName>Ye</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, The People's Liberation Army General Hospital, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Quan</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Thoracic Surgery, Jiangxi Provincial People's Hospital, Nanchang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>Liping</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Xianyang First People's Hospital, Xianyang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Songdi</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0003-1186-3322</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Xi'an No. 1 Hospital, Xi'an, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lei</LastName>
            <ForeName>Tao</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Xi'an Fourth People's Hospital, Xi'an, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Min</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gao</LastName>
            <ForeName>Yanwu</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lu</LastName>
            <ForeName>Xiaodan</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Huanhuan</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Chao</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tang</LastName>
            <ForeName>Baoli</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Zhuyi</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chang</LastName>
            <ForeName>Ting</ForeName>
            <Initials>T</Initials>
            <Identifier Source="ORCID">0000-0002-7546-8017</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>07</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Eur J Neurol</MedlineTA>
        <NlmUniqueID>9506311</NlmUniqueID>
        <ISSNLinking>1351-5101</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007165" MajorTopicYN="N">Immunosuppression Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009157" MajorTopicYN="Y">Myasthenia Gravis</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D057216" MajorTopicYN="N">Propensity Score</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">generalization</Keyword>
        <Keyword MajorTopicYN="N">generalized myasthenia gravis</Keyword>
        <Keyword MajorTopicYN="N">immunosuppression treatment</Keyword>
        <Keyword MajorTopicYN="N">ocular myasthenia gravis</Keyword>
        <Keyword MajorTopicYN="N">propensity score analysis</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>21</Day>
          <Hour>12</Hour>
          <Minute>13</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35188698</ArticleId>
        <ArticleId IdType="doi">10.1111/ene.15292</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>REFERENCES</Title>
        <Reference>
          <Citation>Grob D, Brunner N, Namba T, et al. Lifetime course of myasthenia gravis. Muscle Nerve. 2008;37:141-149.</Citation>
        </Reference>
        <Reference>
          <Citation>Bever CT Jr, Aquino AV, Penn AS, Lovelace RE, Rowland LP. Prognosis of ocular myasthenia. Ann Neurol. 1983;14:516-519.</Citation>
        </Reference>
        <Reference>
          <Citation>Grob D, Arsura EL, Brunner NG, et al. The course of myasthenia gravis and therapies affecting outcome. Ann N Y Acad Sci. 1987;505:472-499.</Citation>
        </Reference>
        <Reference>
          <Citation>Kupersmith MJ. Ocular myasthenia gravis: treatment successes and failures in patients with long-term follow-up. J Neurol. 2009;256:1314-1320.</Citation>
        </Reference>
        <Reference>
          <Citation>Kupersmith MJ, Moster M, Bhuiyan S, et al. Beneficial effects of corticosteroids on ocular myasthenia gravis. Arch Neurol. 1996;53:802-804.</Citation>
        </Reference>
        <Reference>
          <Citation>Mee J, Paine M, Byrne E, King J, Reardon K, O'Day J. Immunotherapy of ocular myasthenia gravis reduces conversion to generalized myasthenia gravis. J Neuro Ophthalmol. 2003;23:251-255.</Citation>
        </Reference>
        <Reference>
          <Citation>Monsul NT, Patwa HS, Knorr AM, et al. The effect of prednisone on the progression from ocular to generalized myasthenia gravis. J Neurol Sci. 2004;217:131-133.</Citation>
        </Reference>
        <Reference>
          <Citation>Sommer N, Sigg B, Melms A, et al. Ocular myasthenia gravis: response to long term immunosuppressive treatment. J Neurol Neurosurg Psychiatry. 1997;62:156-162.</Citation>
        </Reference>
        <Reference>
          <Citation>Zach H, Cetin H, Hilger E, et al. The effect of early prednisolone treatment on the generalization rate in ocular myasthenia gravis. Eur J Neurol. 2013;20:708-713.</Citation>
        </Reference>
        <Reference>
          <Citation>Wong SH, Huda S, Vincent A, et al. Ocular myasthenia gravis: controversies and updates. Curr Neurol Neurosci Rep. 2014;14:421.</Citation>
        </Reference>
        <Reference>
          <Citation>Kerty E, Elsais A, Argov Z, et al. EFNS/ENS Guidelines for the treatment of ocular myasthenia. Eur J Neurol. 2014;21:687-693.</Citation>
        </Reference>
        <Reference>
          <Citation>Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis: 2020 update. Neurology. 2021;96:114-122.</Citation>
        </Reference>
        <Reference>
          <Citation>Li M, Ge F, Guo R, et al. Do early prednisolone and other immunosuppressant therapies prevent generalization in ocular myasthenia gravis in Western populations: a systematic review and meta-analysis. Ther Adv Neurol Disord. 2019;12:1-8.</Citation>
        </Reference>
        <Reference>
          <Citation>Hong YH, Kwon SB, Kim BJ, et al. Prognosis of ocular myasthenia in Korea: a retrospective multicenter analysis of 202 patients. J Neurol Sci. 2008;273:10-14.</Citation>
        </Reference>
        <Reference>
          <Citation>Teo KY, Tow SL, Haaland B, et al. Low conversion rate of ocular to generalized myasthenia gravis in Singapore. Muscle Nerve. 2018;57:756-760.</Citation>
        </Reference>
        <Reference>
          <Citation>Von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. Int J Surg. 2014;12:1495-1499.</Citation>
        </Reference>
        <Reference>
          <Citation>Miguel Angel H, Babette B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology. 2000;11:561-570.</Citation>
        </Reference>
        <Reference>
          <Citation>Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28:3083-3107.</Citation>
        </Reference>
        <Reference>
          <Citation>Benatar M, Kaminski H. Medical and surgical treatment for ocular myasthenia. Cochrane Database Syst Rev. 2012;12:CD005081.</Citation>
        </Reference>
        <Reference>
          <Citation>Liu Z, Feng H, Yeung SC, et al. Extended transsternal thymectomy for the treatment of ocular myasthenia gravis. Ann Thorac Surg. 2011;92:1993-1999.</Citation>
        </Reference>
        <Reference>
          <Citation>Mineo TC, Ambrogi V. Outcomes after thymectomy in class I myasthenia gravis. J Thorac Cardiovasc Surg. 2013;145:1319-1324.</Citation>
        </Reference>
        <Reference>
          <Citation>Schumm F, Wietholter H, Fateh-Moghadam A, Dichgans J. Thymectomy in myasthenia with pure ocular symptoms. J Neurol Neurosurg Psychiatry. 1985;48:332-337.</Citation>
        </Reference>
        <Reference>
          <Citation>Li H, Ruan Z, Gao F, et al. Thymectomy and risk of generalization in patients with ocular myasthenia gravis: a multicenter retrospective cohort study. Neurotherapeutics. 2021;18(4):2449-2457.</Citation>
        </Reference>
        <Reference>
          <Citation>Galassi G, Mazzoli M, Ariatti A, et al. Antibody profile may predict outcome in ocular myasthenia gravis. Acta Neurol Belg. 2018;118:435-443.</Citation>
        </Reference>
        <Reference>
          <Citation>Peeler CE, De Lott LB, Nagia L, et al. Clinical utility of acetylcholine receptor antibody testing in ocular myasthenia gravis. JAMA Neurol. 2015;72:1170-1174.</Citation>
        </Reference>
        <Reference>
          <Citation>Guo RJ, Gao T, Ruan Z, et al. Risk factors for generalization in patients with ocular myasthenia gravis: a multicenter retrospective cohort study. Neurol Ther. 2021;11(1):73-86.</Citation>
        </Reference>
        <Reference>
          <Citation>Evoli A, Batocchi AP, Minisci C, et al. Therapeutic options in ocular myasthenia gravis. Neuromuscul Disord. 2001;11:208-216.</Citation>
        </Reference>
        <Reference>
          <Citation>Tackenberg B, Hemmer B, Oertel WH, et al. Immunosuppressive treatment of ocular myasthenia gravis. BioDrugs. 2001;15:369-378.</Citation>
        </Reference>
        <Reference>
          <Citation>Hehir MK, Burns TM, Alpers J, et al. Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients. Muscle Nerve. 2010;41:593-598.</Citation>
        </Reference>
        <Reference>
          <Citation>Palace J, Newsom-Davis J, Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology. 1998;50:1778-1783.</Citation>
        </Reference>
        <Reference>
          <Citation>Kim YH, Shin HY, Kim SM. Long-term safety and efficacy of tacrolimus in myasthenia gravis. Yonsei Med J. 2019;60:633-639.</Citation>
        </Reference>
        <Reference>
          <Citation>Zhao CB, Zhang X, Zhang H, et al. Clinical efficacy and immunological impact of tacrolimus in Chinese patients with generalized myasthenia gravis. Int Immunopharmacol. 2011;11:519-524.</Citation>
        </Reference>
        <Reference>
          <Citation>Oosterhuis HJ. The natural course of myasthenia gravis: a long term follow up study. J Neurol Neurosurg Psychiatry. 1989;52:1121-1127.</Citation>
        </Reference>
        <Reference>
          <Citation>Mee J, Paine M, Byrne E, et al. Immunotherapy of ocular myasthenia gravis reduces conversion to generalized myasthenia gravis. J Neuroophthalmol. 2003;23:251-255.</Citation>
        </Reference>
        <Reference>
          <Citation>Verma R, Wolfe GI, Kupersmith MJ. Ocular myasthenia gravis - How effective is low dose prednisone long term? J Neurol Sci. 2021;420:117274.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
